NEOG
HealthcareNeogen Corporation · Medical - Diagnostics & Research · $2B
What is Neogen Corporation?
Neogen Corporation develops and markets products designed to protect food supplies and support animal health worldwide. Operating from Lansing, Michigan, the company serves food producers, processors, laboratories, and veterinary markets across the globe.
Neogen operates through two segments: Food Safety and Animal Safety. The Food Safety segment produces diagnostic test kits that detect pathogens, allergens, toxins, pesticide residues, and sanitation concerns in food and animal feed. The Animal Safety segment supplies veterinary instruments, pharmaceuticals, vaccines, parasiticides, disinfectants, and genomics testing services. Together, these segments serve food processors, grain producers, meat and poultry handlers, dairies, pharmaceutical manufacturers, and animal health researchers.
Neogen was founded in 1989 and is headquartered in Lansing, Michigan.
- Foodborne pathogen and allergen diagnostic test kits
- AccuPoint Advanced rapid sanitation testing system
- Veterinary pharmaceuticals, vaccines, and parasiticides
- Genomics testing services for animal safety markets
- Drug residue and pesticide detection immunoassay kits
Is NEOG a Good Stock to Buy?
UQS Score rates NEOG as Below Average overall.
Among the five pillars, Risk and Valuation stand out as relative positives. The Risk profile suggests the business carries a manageable financial risk profile compared to many peers, while the Valuation pillar indicates the stock is not obviously expensive relative to its fundamentals — a meaningful consideration for investors watching entry points.
Quality, Moat, and Growth all register as Weak, reflecting challenges in profitability consistency, competitive differentiation, and revenue expansion that weigh on the composite score.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does NEOG pay dividends?
No — Neogen Corporation does not currently pay a dividend.
Neogen does not currently pay a dividend. For a company navigating integration efforts and investing in expanding its food and animal safety product portfolio, retaining capital for operational priorities is a common strategic choice. Income-focused investors should factor this into their assessment when comparing NEOG to dividend-paying peers in the healthcare and life sciences space.
When does NEOG report earnings?
Neogen Corporation reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
The company's recent results have reflected the challenges captured in its Weak Quality and Growth pillar ratings — revenue expansion has been modest and profitability metrics have faced pressure. Investors should track whether operational improvements translate into stronger fundamentals over coming quarters.
For the most recent quarter's results and guidance, visit Neogen Corporation's investor relations page directly.
NEOG Price History
-79.6% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Neogen Corporation?
Based on Neogen Corporation's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
NEOG Long-term Outlook
Neogen's fundamental outlook is shaped by a Weak Growth pillar alongside a Good Risk profile. The business operates in a structurally important niche — food safety testing and animal health — where regulatory tailwinds and food supply scrutiny provide a long-term demand backdrop. However, translating that market opportunity into consistent top-line and bottom-line growth remains the central challenge. The Good Risk rating suggests the balance sheet is not a near-term concern, which provides some operational runway.
Growth drivers
- Growing global demand for food safety testing and pathogen detection
- Expansion of animal health and genomics testing services
- Regulatory requirements driving adoption of diagnostic products
Key risks
- Weak profitability and quality metrics limiting reinvestment capacity
- Competitive pressure in both food safety and animal health markets
- Integration complexity from prior acquisitions weighing on margins
NEOG vs Peers
Neogen operates in a specialized corner of the healthcare and life sciences market, where it faces competition from companies focused on diagnostics and genomics.
GRAIL focuses on early cancer detection through multi-cancer blood tests, targeting a very different end market than Neogen's food and animal safety diagnostics.
BillionToOne specializes in molecular diagnostics for rare genetic diseases and prenatal testing, serving clinical rather than food or animal safety applications.
Twist Bioscience provides synthetic DNA and genomics tools primarily to research and biopharma customers, with less direct exposure to food safety markets.
Frequently Asked Questions
What does Neogen Corporation do?
Neogen develops, manufactures, and markets products for food safety and animal safety worldwide. Its Food Safety segment offers diagnostic test kits for detecting pathogens, allergens, and contaminants in food and feed. Its Animal Safety segment provides veterinary pharmaceuticals, vaccines, parasiticides, and genomics testing services for animal health markets.
Does NEOG pay dividends?
Neogen does not currently pay a dividend. The company has historically prioritized reinvesting capital into its product portfolio and operations rather than returning cash to shareholders through distributions. Investors seeking income should consider this when evaluating NEOG against dividend-paying alternatives.
When does NEOG report earnings?
Neogen reports financial results on a quarterly basis, in line with standard US-listed company practice. For confirmed upcoming earnings dates and the latest quarterly results, check Neogen Corporation's official investor relations page, as specific dates can shift.
Is NEOG a good stock to buy?
UQS Score rates NEOG as Below Average, reflecting Weak ratings across Quality, Moat, and Growth pillars. The Risk and Valuation pillars offer some offset. Whether NEOG fits a portfolio depends on individual goals — the complete pillar breakdown is available to UQS Pro members.
Is NEOG overvalued?
The UQS Valuation pillar for NEOG is rated Good, suggesting the stock does not appear obviously overpriced relative to its fundamentals. However, valuation alone does not determine investment merit — weak quality and growth metrics are important context for any valuation assessment.
How does NEOG compare to its competitors?
Neogen's listed peers — GRAIL, BillionToOne, and Twist Bioscience — operate in adjacent diagnostics and genomics spaces but serve different end markets. Neogen's focus on food and animal safety testing gives it a distinct regulatory and commercial niche. Full UQS Score comparisons across pillars are available to Pro members.
What is NEOG's market cap bracket?
Neogen Corporation is classified as a mid-cap company. This places it in a segment of the market that typically offers more liquidity than small-cap peers while still carrying meaningful growth and operational execution risk compared to large-cap incumbents.
Who founded Neogen Corporation?
Neogen Corporation was founded in 1989. Details on its founding team are widely available through the company's official history and public filings. The company has grown from a Michigan-based startup into a global food and animal safety diagnostics business over more than three decades.
Is NEOG a long-term quality indicator stock?
As a long-term quality indicator, NEOG's current UQS profile presents challenges. Weak Quality, Moat, and Growth ratings suggest the business has not yet demonstrated the durable competitive advantages and consistent profitability that typically characterize high-quality long-term holdings. The Good Risk rating provides some stability context.
What is the main competitive advantage of Neogen Corporation?
Neogen's primary positioning comes from its specialized focus on food and animal safety diagnostics — a niche with regulatory tailwinds and consistent demand from food processors and animal health markets. However, the UQS Moat pillar currently rates as Weak, indicating that durable competitive differentiation remains a work in progress.
What sector does NEOG belong to?
Neogen Corporation is classified within the Healthcare sector, specifically operating at the intersection of diagnostics and life sciences tools. Its products serve food safety laboratories, agricultural processors, and veterinary markets — a specialized segment within the broader healthcare and diagnostics industry.
Is NEOG a growth stock or value stock?
Based on UQS pillar labels, NEOG does not fit cleanly into either category. The Growth pillar is rated Weak, meaning it lacks the expansion profile typical of growth stocks. The Valuation pillar is rated Good, suggesting it is not priced at a premium — but weak fundamentals temper any straightforward value characterization.
Unlock Full NEOG Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access detailed financial metrics behind each pillar
- ✓Compare NEOG to sector peers on quality and valuation
- ✓Track pillar changes across quarterly earnings updates
- ✓Screen for stronger-rated mid-cap healthcare alternatives
- ✓Get the complete analyst-style view in one dashboard
Pro Analysis
NEOG — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 7, 2026 | 35.4 | 9.3 | 23.0 | 34.8 | 71.9 | 63.9 | +0.1 |
| Apr 29, 2026 | 35.3 | 9.3 | 23.0 | 34.8 | 71.9 | 63.2 | 0.0 |
| Apr 26, 2026 | 35.3 | 9.3 | 23.0 | 34.8 | 71.9 | 63.0 | 0.0 |
| Apr 20, 2026 | 35.3 | 9.3 | 23.0 | 34.8 | 71.9 | 63.1 | +0.1 |
| Apr 19, 2026 | 35.2 | 9.3 | 23.0 | 34.8 | 71.9 | 62.8 | -0.1 |
| Apr 14, 2026 | 35.3 | 9.3 | 23.0 | 34.8 | 71.9 | 63.1 | 0.0 |
| Apr 12, 2026 | 35.3 | 9.3 | 23.0 | 34.8 | 71.9 | 63.0 | 0.0 |
| Apr 11, 2026 | 35.3 | 9.3 | 23.0 | 34.9 | 71.9 | 63.0 | -1.1 |
| Apr 8, 2026 | 36.4 | 6.6 | 23.0 | 35.3 | 81.2 | 64.7 | 0.0 |
| Apr 2, 2026 | 36.4 | 6.8 | 23.0 | 35.3 | 81.2 | 64.8 | — |
NEOG — Pillar Breakdown
Quality
— 9.5/100 (25%)Neogen Corporation currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 35.0/100 (20%)Neogen Corporation shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 71.9/100 (15%)Neogen Corporation maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 63.6/100 (15%)Neogen Corporation trades at a reasonable valuation with decent earnings yield and FCF multiples.
Inverse of forward P/E — higher yield means cheaper stock.
P/E relative to earnings growth — lower is more attractive.
Moat
— 23/100 (25%)Neogen Corporation operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for NEOG.
Score Composition
Financial Data
More Stock Analysis
How is the NEOG UQS Score Calculated?
The UQS (Unified Quality Score) for Neogen Corporation is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Neogen Corporation's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Neogen Corporation is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.